#PAGE_PARAMS# #ADS_HEAD_SCRIPTS# #MICRODATA#

Search results: (10000)



News Effect of Combination Therapy on Symptoms of Allergic Rhinitis

The aim of the study presented below by authors from the USA was to evaluate the efficacy, safety, and tolerability of treatment with the nasal spray GSP301 containing a fixed combination of active ingredients, compared to placebo and monotherapies during a 14-day therapy in adult and adolescent patients with allergic rhinitis.
Source: Life Without Allergic Rhinitis 24. 3. 2022

News Comparison of the Risk of Interstitial Lung Disease in Patients with RA with Biological and Targeted Disease-Modifying Antirheumatic Therapy

The authors of a newly published study sought to answer whether the risk of developing interstitial lung disease in patients with rheumatoid arthritis (RA) is affected by the administration of biological or targeted disease-modifying antirheumatic therapy. They analyzed data from more than 28,000 patients with RA.
Source: Arthritis 8. 6. 2023

News Analysis of Data from the EMPEROR-Preserved Study Revealed Whether Blood Pressure Affects the Effectiveness of Empagliflozin in Patients with Heart Failure with Preserved Ejection Fraction

Hypertension is among the most common etiological factors of heart failure with preserved ejection fraction (HFpEF), where pressure overload of the left ventricle leads to its eccentric hypertrophy and diastolic dysfunction. According to recent study results, empagliflozin significantly reduces the risk of cardiovascular (CV) complications in patients with HFpEF. The EMPEROR-Preserved sub-analysis further examined the impact of baseline systolic blood pressure (sBP) on treatment outcomes and patient prognosis.
Source: Heart Failure 19. 6. 2023

News Economic Costs and Concomitant FVIII Consumption in Hemophilia Patients Treated with Emicizumab in the 1st Year − A US Experience

The authors of a recent study, summarizing real-world experience from the US, focused on the concomitant consumption of FVIII (Factor VIII) concentrates during emicizumab prophylaxis and the financial costs in the first year after starting emicizumab treatment.
Source: Hemophilia 27. 11. 2023

News Impact of the combination of bevacizumab with erlotinib in patients with NSCLC and EGFR mutation on overall survival and time to disease progression

Dual inhibition of the epidermal growth factor receptor (EGFR) and vascular endothelial growth factor (VEGF) can delay resistance to chemotherapy in patients with advanced-stage non-small cell lung cancer (NSCLC). The study presented below examined the efficacy and safety of the erlotinib + bevacizumab combination compared to erlotinib monotherapy in these patients.
Source: Oncological Treatment 21. 11. 2022

News Can Erdostein Help in Treating Infections Related to Biofilm Formation?

One of the reasons for the very difficult treatment of diseases caused by resistant bacterial strains is the significant ability of these infection-causing agents to form biofilms. What exactly is a biofilm? Which bacteria are likely to form it, and how can erdostein help in the fight against it?
Source: Cough Therapy 8. 4. 2022

News Adding Paracetamol to Tramadol to Relieve Early Postoperative Pain After Lumbar Discectomy

A recently published study is likely the first prospective randomized controlled trial comparing the postoperative analgesic efficacy of a tramadol and paracetamol combination versus tramadol alone. Its results favor the combination, with significantly lower pain scores during the first 30 minutes and reduced tramadol consumption within the first 24 hours post-surgery.
Source: Pharmacotherapy of Pain 4. 12. 2020

News Efficacy and Safety of Enoxaparin in Hospitalized Patients with Severe Renal Insufficiency

A study evaluating the effect of thromboprophylaxis with enoxaparin at a dose of 20 mg/day in adult patients with renal failure compared the incidence of venous thromboembolism (VTE) with published results in patients without renal insufficiency who were prophylactically treated with enoxaparin at a dose of 40 mg/day. The authors also focused on the incidence of bleeding.
Source: Thromboprophylaxis 13. 6. 2022

News Major Orthopedic Procedures in Patients with Inhibitor Treated with Emicizumab

Italian authors presented the results of a study of a small series of hemophilia patients with inhibitors treated with emicizumab, who underwent major orthopedic surgery, at the World Federation of Hemophilia (WFH) forum. This information is very important, as emicizumab, being a new drug, offers new perspectives on how to ensure surgery for these highly risky patients.
Source: Quality Life Even with Hemophilia 28. 7. 2020

News Ceftarolin Fosamil in Patients with Complicated Skin and Soft Tissue Infections Admitted to ICU

In a recently published data analysis from the COVERS 3 study, the antibiotic ceftarolin fosamil was evaluated in patients with complicated skin and soft tissue infections (cSSTI) admitted to the intensive care unit (ICU), and its effectiveness was compared with patients with the same diagnosis and treatment who did not require ICU admission.
Source: Anti-Infectives 17. 12. 2020

News Candesartan Could Ameliorate the Cytokine Storm in COVID-19 Infection

Scientists from Bethesda, USA, experimentally found the upregulation of the same genes during COVID-19 infection as with the action of glutamate (simulating aging and Alzheimer's disease) and the normalization of their expression by candesartan. Considering that many of these genes are involved in the cytokine storm in COVID-19, the mentioned results support the hypothesis that sartans − or at least candesartan − could mitigate the cytokine storm in patients with severe COVID-19.
Source: Sartans in the Treatment of Hypertension 27. 1. 2021

Journal articles Non-Small Cell Lung Cancer with Estrogen Receptors and ALK Positivity

Author of the article: L. Žarnayová, V. Kolek, J. Bouchal, J. Ehrmann Source: Klinická onkologie | 6/2018 11. 12. 2018

News Effect of Denosumab and Zoledronic Acid on Overall Survival in Patients with Metastatic Lung Cancer

In 30-40% of patients with non-small cell lung cancer (NSCLC), bone metastases develop during the course of the disease, causing so-called skeletal-related events (SREs). These events cause pain, increase morbidity, and reduce quality of life and mobility in patients. Antiresorptive agents, such as the bisphosphonate zoledronic acid or the osteoclast maturation and differentiation inhibitor denosumab, are used to prevent the occurrence of SREs. An exploratory analysis compared the effect of administering denosumab and zoledronic acid on the survival of patients with metastatic disease.
Source: Prevention of Bone Events 12. 9. 2022

News MS in the Digital Age: Doctor as a Lifebuoy in the Sea of Information

How to offer a helping hand to patients amidst the flood of information and why is communication perhaps more important than ever? And what should the standards in the doctor-patient relationship with multiple sclerosis be? This unusual topic was explored in a publication in the journal Neurosciences.
Source: Multiple Sclerosis 15. 8. 2023

News Prof. Roman Chlíbek: Role of Multivalent Pneumococcal Conjugate Vaccines in Healthy and Premature Children

Children are frequent carriers of pneumococci, which can cause both common non-invasive and more severe, life-threatening invasive pneumococcal diseases, especially in children under 1 year of age and in people over 65 years old. Almost a year ago, a pediatric indication for a 15-valent pneumococcal vaccine was approved, which is enriched with 2 new serotypes and, according to study results, appears to be potentially more effective even in protecting against serotype 3. So what are the vaccination options for healthy immunocompetent children, and what benefits does this vaccine offer for premature infants? Professor Roman Chlíbek, chair of the Czech Vaccinology Society ČLS JEP, answered these questions in his presentation at the June Interdisciplinary Conference of PLDD.
Source: Regular Vaccination 25. 8. 2023

News The safety of dupilumab allows treatment of atopic dermatitis without routine laboratory monitoring

The first comprehensive analysis of laboratory data from 3 clinical trials with dupilumab assessed the incidence of clinically significant changes in hematological or biochemical parameters in patients with moderate to severe atopic dermatitis.
Source: Systemic treatment of atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyposis – Type 2 inflammation 14. 12. 2020

News Effectiveness of Idarucizumab Reversal Effect

It is, of course, a great advantage if doctors have a specific substance available that counteracts the effect of oral anticoagulants in urgent need. Idarucizumab is a humanized monoclonal antibody that binds dabigatran with high affinity. The drug was approved for clinical use based on an interim analysis of the results of 90 patients enrolled in the RE-VERSE AD study. What conclusions were drawn based on the results of the entire study population?
Source: Anticoagulant Treatment 21. 4. 2022

News Brigatinib in Patients with ALK+ NSCLC – Final Results of the J-ALTA Clinical Study

At this year's American Society of Clinical Oncology (ASCO) conference held in Chicago in early June 2022, the final results of the J-ALTA clinical study were presented. So how did brigatinib perform in the treatment of patients with ALK-positive NSCLC who were refractory to alectinib?
Source: Non-Small Cell Lung Cancer 12. 9. 2022

News Benefit of ixazomib in patients with relapsed/refractory multiple myeloma in routine clinical practice

The results of treating relapsed or refractory multiple myeloma in real-world routine clinical practice were published by a broad team of Czech experts in the journal BMC Cancer.
Source: Hematologic Malignancies 10. 3. 2021

News Monotherapy with Bimatoprost in Patients with Glaucoma and Ocular Hypertension

Can monotherapy with bimatoprost be sufficiently effective in controlling intraocular pressure in non-responders to previous treatments? This is the question posed by British researchers in the presented study.
Source: Treatment of Glaucoma 4. 5. 2020

News Basic Information on the Spread and Course of COVID-19 Infection in China: What We Know So Far?

Currently, we are experiencing a worldwide outbreak of COVID-19 infection caused by the SARS-CoV-2 virus, with the first cases identified in December 2019 in Wuhan, China. As of March 18, 2020, according to WHO information, the virus has spread to six continents and a total of 179,111 people worldwide were infected with COVID-19, of whom 7,426 have died from the disease. Sharing transparent, valid, and relevant information is one of the cornerstones of the fight to mitigate the impact of this infection. Chinese authors recently published a summary of current knowledge on the epidemiology, clinical manifestations, diagnosis, treatment, and prevention of COVID-19, valid as of March 2, 2020, in the International Journal of Infectious Diseases.
Source: Anti-Infectives 17. 3. 2020

News Importance of pH in Care for Stoma Patients

Maintaining good quality peristomal skin and preventing complications related to the stoma site are integral parts of comprehensive care for patients with stomas. The pH of the skin also plays an important role in this issue, as it can significantly affect the condition of the skin, the development of complications, the quality of life of patients, and consequently impact the economic aspect of stoma care.
Source: Ostomy 19. 3. 2020

News Prevalence and Clinical Impact of Overweight and Obesity in the Hemophilia Population

Obesity is classified as a lifestyle disease with increasing prevalence and a rising contribution to morbidity and mortality in the general population. The epidemic of overweight and obesity also does not spare individuals with hemophilia. According to epidemiological data, the prevalence of obesity is also increasing in this population, causing a number of complications in many health aspects.
Source: Hemophilia with Movement 30. 5. 2022

News Development and Benefits of Intestinal Gel LECIG for Patients with Parkinson's Disease

Patients with advanced Parkinson's disease, for whom the current regimen of orally and transdermally administered medications is insufficient for symptom relief, now have a new treatment option. It involves the continuous administration of an intestinal gel that combines three effective antiparkinsonian drugs.
Source: Parkinson's Disease 10. 3. 2023

News Luck in Unluckiness: Influence of Anticoagulant Therapy on Severity of Stroke in Atrial Fibrillation

A recent Swiss study evaluated the severity, complications, and outcomes of cerebrovascular accidents (CVAs) in patients with atrial fibrillation considering prior anticoagulant therapy use and its type. This allowed for a comparison between direct oral anticoagulants (DOACs) and vitamin K antagonists (VKAs).
Source: Anticoagulant Treatment 25. 4. 2022

1 7 8 9 10 11 400
Topics Journals
Login
Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

#ADS_BOTTOM_SCRIPTS#